NCT00060476已完成3 期
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Rofecoxib in Decreasing the Risk of Prostate Cancer (ViP Study)
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 15,000
- 主要终点
- Time to prostate cancer
研究概览
简要总结
To determine the efficacy and safety of an investigational compound (MK0966) for the prevention of prostate cancer.
详细描述
The duration of treatment is 6 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 50 Years 至 75 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Time to prostate cancer
时间窗: Duration of Treatment
次要结局
- Time to aggressive prostate cancer(Duration of Treatment)
研究者
相似试验
已完成
3 期
Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)Major Depressive DisorderNCT00048594Merck Sharp & Dohme LLC800
已完成
3 期
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)Major Depressive DisorderNCT00035048Merck Sharp & Dohme LLC540
已完成
3 期
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)Major Depressive DisorderNCT00035282Merck Sharp & Dohme LLC450
已完成
2 期
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's DiseaseCrohn's DiseaseNCT00101946GlaxoSmithKline17
已完成
2 期
Prevention Of Recurrence Of Atrial FibrillationFibrillation, AtrialNCT00041496GlaxoSmithKline520